Premature ejaculation (PE) is by far the most common male sexual complaint, with millions of men affected all over the world. It is estimated that up to 20-30% of all men may be suffering from various forms of PE. A variety of filler materials are widely used nowadays for soft tissue augmentation. The appropriate filler can restore symmetry, volume and create a smooth skin surface The aim of this pilot study was to evaluate the therapeutic effect of hyaluronic acid gel injection in patients with PE. Sixty men with self-reported PE who were referred to our outpatient andrology clinic (between January 2007 and January 2008) were included in this study. Participants were randomly assigned using random sampling numbers into two distinct groups. Group A (n = 30) received a single injection of 2 ml of hyaluronic acid gel (Hyalift 3.5% micronised hyaluronic acid) using the previously described fan technique. Group B (n = 30) received a single injection of 2 ml of hyaluronic acid gel using the multiple puncture technique. Twenty-three patients (46.9%) received injection by the fan technique, while 26 patients (53.1%) received it through the multiple-point technique. The mean intravaginal ejaculation latency time (IELT) increased significantly from 2.12 ± 1.16 to 7.71 ± 7.86 min, after 1 month of injection and then dropped to 5.32 ± 3.52 min, but still remaining significantly higher than the baseline values. Results from our present pilot study demonstrated the usefulness of the application of hyaluronic acid dermal fillers in the treatment of PE; however, further investigations in large cohorts with longer follow-up are definitely needed to obtain more consistent results.

No abstract

Introduction: In order to accurately assess the extent of chronic pelvic pain syndrome (CPPS) and to objectively measure symptoms for natural history studies and to assess the outcome parameters for clinical trials, the National Institutes of Health (NIH) Chronic Prostatitis Collaborative Research Network developed and validated the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). The aim of the current study was to develop and validate a fluent and comprehensive Arabic version of the NIH-CPSI. Methods: This study consisted of 80 consecutive male patients affected by CPPS and 80 healthy controls who were asked to complete the Arabic version of the NIH-CPSI. The translation was performed by a group consisting of an andrologist and professional translators. Psychometric data were collected. Results: Of the 160 subjects enrolled, 82 (50 patients and 32 controls) completed the study. The total Arabic NIH-CPSI scores and the scores of each subscale differed significantly between the two groups with good discriminant validity. The questionnaire had also a high internal consistency. Conclusion: The present study provides the Arabic version of the NIH-CPSI and recognizes it as a valid and reliable tool in the assessment of local patients with CPPS.

Background: Aromatase inhibitors (AI) can boost endogenous testosterone production without increasing circulating estrogen levels, as shown with estrogen receptor modulators, Aim and Objectives: The study's goal was to determine the efficacy of aromatase inhibitor medication in improving spermatogenesis in oligozoospemic and azoospermic males, as well as its relationship to sexuality. Subjects and methods: This study was done on eighty man subjects joining the outpatient clinic of Andrology, Kasr El Aini Hospital, Cairo University during the peroid from April 2018 – April 2020, and they were divided into (2) groups, 40 subjects in each group.  Results: There was a statistically significant difference in serum total testosterone measured before and after treatment in normal FSH patients with a p value ≤ 0.05. There was a notably not important change in sexual desire questionnaire measured before and after treatment in normal FSH patients with a p value > 0.05, Conclusion: ERs and aromatase share topographic sites in the brain with pheromones, indicating that estrogen influences both early sexual maturation and sexual behavior in adults. Estrogen can maintain libido while also influencing the number of serotonin receptors in the brain, which modulates mood, mental state, cognition, and emotion.

Background: Aromatase inhibitors (AI) can boost endogenous testosterone production without increasing circulating estrogen levels, as shown with estrogen receptor modulators, Aim and Objectives: The study's goal was to determine the efficacy of aromatase inhibitor medication in improving spermatogenesis in oligozoospemic and azoospermic males, as well as its relationship to sexuality. Subjects and methods: This study was done on eighty man subjects joining the outpatient clinic of Andrology, Kasr El Aini Hospital, Cairo University during the peroid from April 2018 – April 2020, and they were divided into (2) groups, 40 subjects in each group.  Results: There was a statistically significant difference in serum total testosterone measured before and after treatment in normal FSH patients with a p value ≤ 0.05. There was a notably not important change in sexual desire questionnaire measured before and after treatment in normal FSH patients with a p value > 0.05, Conclusion: ERs and aromatase share topographic sites in the brain with pheromones, indicating that estrogen influences both early sexual maturation and sexual behavior in adults. Estrogen can maintain libido while also influencing the number of serotonin receptors in the brain, which modulates mood, mental state, cognition, and emotion.